使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Greetings and welcome to the Align Technology's third-quarter 2015 earnings conference call. (Operator Instructions). I would now like to turn the conference over to your host, Shirley Stacy. Thank you. You may now begin.
各位好,歡迎參加 Align Technology 2015 年第三季財報電話會議。(接線員指示)。現在我想把會議交給今天的主持人 Shirley Stacy。謝謝。您現在可以開始。
Shirley Stacy - VP Corporate Communications & IR
Shirley Stacy - VP Corporate Communications & IR
Good afternoon and thank you for joining us. I am Shirley Stacy, Vice President of Corporate Communications and Investor Relations. Joining me today is Joe Hogan, President and CEO, and David White, CFO.
各位下午好,感謝各位加入我們。我是 Shirley Stacy,企業傳播與投資人關係副總裁。今天與我一同出席的有總裁兼執行長 Joe Hogan,以及財務長 David White。
We issued third-quarter 2015 financial results today via Marketwire, which is available on our website at investor.aligntech.com. Today's conference call is being audio webcast and will be archived on our website for approximately 12 months.
我們今天已透過 Marketwire 發布 2015 年第三季財務結果,您可在我們的網站 investor.aligntech.com 上取得。今天的電話會議將以音訊網路直播,並會在我們網站上存檔約 12 個月。
A telephone replay will be available today by approximately 5:30 PM Eastern time through 5:30 PM Eastern time on October 30. To access the telephone replay, domestic callers should dial 877-660-6853 with conference number 13621393, followed by pound. International callers should dial 201-612-7415 with the same conference number.
電話重播將於今日美東時間約下午 5:30 起提供,並持續至 10 月 30 日美東時間下午 5:30。如需收聽電話重播,美國境內來電者請撥 877-660-6853,會議號碼 13621393,然後按井字鍵。國際來電者請撥 201-612-7415,並使用相同的會議號碼。
As a reminder, the information that the presenters discuss today will include forward-looking statements, including statements about Align's future events, product outlook, and the expected financial results for the fourth quarter of 2015. These forward-looking statements are only predictions and involve risks and uncertainties that are set forth in more detail in our most recent periodic reports filed with the Securities and Exchange Commission. Actual results may vary significantly and Align expressly assumes no obligation to update any forward-looking statement.
提醒各位,今天簡報者所討論的資訊將包含前瞻性陳述,包括關於 Align 未來事件、產品展望,以及 2015 年第四季預期財務結果的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性;相關內容已在我們最近向美國證券交易委員會提交的定期報告中更詳細說明。實際結果可能有重大差異,Align 明確表示不承擔更新任何前瞻性陳述的義務。
We have posted a set of GAAP and non-GAAP historical financial statements, including the corresponding reconciliations, and our third-quarter conference call slides on our website under quarterly results. Please refer to these files for more detailed information.
我們已在網站的「季度結果」專區張貼一套 GAAP 與非 GAAP 歷史財務報表(含相對應的調節表),以及第三季電話會議簡報投影片。如需更詳細資訊,請參閱這些檔案。
With that, I will turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?
接下來,我將把電話交給 Align Technology 總裁兼執行長 Joe Hogan。Joe?
Joe Hogan - President, CEO
Joe Hogan - President, CEO
Thanks, Shirley. Good afternoon and thanks for joining us.
謝謝,Shirley。各位下午好,感謝各位加入我們。
On our call today, I will provide some financial highlights and then briefly discuss the performance of our two operating segments, Invisalign Clear Aligners and scanner and services. David will provide more detail on our financials and discuss our outlook for the fourth quarter.
在今天的電話會議中,我將先提供一些財務重點,接著簡要說明我們兩個營運部門的表現:Invisalign 隱形矯正器,以及掃描器與服務。David 將更詳細說明我們的財務狀況,並討論第四季展望。
Q3 was another good quarter, with revenue and EPS above the high end of our guidance. Our results were driven by strong Invisalign case volume, up 2% sequentially and 23% year over year, with growth across all customer channels and geographies. North America volumes grew 18.6% year over year and our international geographies were up 35% compared to last year. This growth was driven by continued momentum in EMEA and APAC, progress in North America, expansion in our low-stage product segment, and seasonally strong uptick in teenage patients.
第三季是另一個表現良好的季度,營收與每股盈餘(EPS)均高於我們財測區間的上緣。我們的成果主要來自 Invisalign 病例量強勁,較前一季成長 2%,較去年同期成長 23%,且所有客戶通路與各地區皆呈現成長。北美病例量較去年同期成長 18.6%,國際地區則較去年成長 35%。此成長動能來自 EMEA 與 APAC 的持續加速、北美的進展、我們低階段產品區隔的擴張,以及青少年患者在季節性因素帶動下的強勁增加。
In North America, Invisalign volume was up both sequentially and year over year, with the highest year-over-year growth rate for North America in three years. Sequential growth was better than expected, driven by seasonally strong teenage demand in the ortho channel, where we had another record quarter for utilization at 9.9 cases per doctor. This is the third consecutive record quarter.
在北美,Invisalign 病例量無論較前一季或較去年同期皆成長,且北美的年增率為三年來最高。較前一季的成長優於預期,主要由矯正通路中季節性強勁的青少年需求所帶動;我們的使用率也再創單季新高,達到每位醫師 9.9 例。這已是連續第三季創下新紀錄。
On a year-over-year basis, growth was driven by both orthos and GPs, reflecting continued adoption of Invisalign by existing ortho customers and expansion of our GP dentist base.
以年對年來看,成長同時來自矯正專科醫師與一般牙醫(GP),反映既有矯正客戶對 Invisalign 的持續採用,以及我們一般牙醫客戶基礎的擴張。
Our investments in sales force effectiveness are producing good results. We are pleased with the progress we see in North America. Customers are responding positively to our new sales structure and we expect to continue to make incremental investments in go to market, clinical education, and customer support in this important market.
我們在銷售團隊效能上的投資正產生良好成果。我們對北美所見到的進展感到滿意。客戶對我們新的銷售架構反應正面,我們預期將在這個重要市場持續逐步增加在市場推進(go-to-market)、臨床教育與客戶支援方面的投資。
Invisalign volume for international doctors was up sequentially and year over year. Our international volume continues to be very strong across all countries in both EMEA and Asia-Pacific, which increased 31.5% and 41%, respectively. The continued strong growth for international was driven by continued adoption of Invisalign in EMEA and expansion of our customer base in APAC.
國際醫師的 Invisalign 病例量較前一季及較去年同期皆成長。我們的國際病例量在 EMEA 與亞太地區各國持續非常強勁,兩者分別成長 31.5% 與 41%。國際市場的持續強勁成長,主要由 EMEA 對 Invisalign 的持續採用,以及 APAC 客戶基礎的擴張所帶動。
On a sequential basis, Invisalign volume was better than expected and strong growth in APAC helped offset the seasonally slower period in EMEA. In EMEA, our year-over-year growth continued across all major regions, with strong performance by Spain, Portugal, France, and the UK.
以季對季來看,Invisalign 病例量優於預期,APAC 的強勁成長有助於抵消 EMEA 季節性較慢的期間。在 EMEA,我們的年對年成長在所有主要區域皆持續,西班牙、葡萄牙、法國與英國表現強勁。
Increased coverage and sales execution continues to build strong momentum. We have a good balance of growth from newly trained and existing customers.
覆蓋率提升與銷售執行力持續累積強勁動能。我們在新受訓客戶與既有客戶所帶來的成長之間,維持良好的平衡。
In September, we hosted our eighth EMEA summit, our largest to date with almost 500 doctors, including 75 from APAC, coming together for an intense clinical education and peer-to-peer networking conference for Invisalign providers. The program focused on building clinical confidence and expanding early adoption of recent innovations, like Invisalign G5 and G6 and ClinCheck Pro. We were pleased to hear consistent and constant feedback throughout the summit that doctors are more confident using Invisalign for more complex cases.
9 月,我們舉辦第八屆 EMEA 高峰會,規模為歷來最大,近 500 位醫師參與,其中包含 75 位來自 APAC;大家齊聚一堂,參加針對 Invisalign 提供者的密集臨床教育與同儕交流會議。本次議程聚焦於建立臨床信心,並擴大對近期創新(如 Invisalign G5、G6 與 ClinCheck Pro)的早期採用。我們很高興在高峰會期間持續聽到一致的回饋:醫師對於使用 Invisalign 處理更複雜病例更有信心。
In Asia-Pacific, Q3 was another record quarter in almost every major country, with China and Japan leading the growth. China now represents our sixth largest country market globally. Q3 utilization was consistent with the prior year and growth reflects continued expansion of our customer base in the region.
在亞太地區,第三季在幾乎所有主要國家再度創下單季新高紀錄,其中以中國與日本帶動成長。中國目前已成為我們全球第六大國別市場。第三季使用率與前一年一致,而成長反映該地區客戶基礎的持續擴張。
During the quarter, we continued commercialization activities for the Invisalign G6 across the region, with numerous clinical education events in New Zealand, Hong Kong, Taiwan, Singapore, Japan, and Thailand. In collaboration with Sunny Dental, we helped open the first Invisalign-dedicated clinic in Beijing.
本季期間,我們持續在區域內推動 Invisalign G6 的商業化活動,並在紐西蘭、香港、台灣、新加坡、日本與泰國舉辦多場臨床教育活動。我們與 Sunny Dental 合作,協助在北京開設第一家專注於 Invisalign 的診所。
In the important teen segment, the total number of Invisalign cases in Q3 increased 22.3% year over year. This reflects continued adoption across our customer channels. On a 12-month basis, over 134,000 teenagers started treatment with Invisalign this past year.
在重要的青少年區隔中,第三季 Invisalign 病例總數較去年同期增加 22.3%。這反映我們各客戶通路的持續採用。以過去 12 個月計算,去年有超過 134,000 名青少年開始使用 Invisalign 進行治療。
Product innovation remains core to our long-term growth and ability to accelerate adoption of Invisalign treatment in both the adult and teenage segments. The extensive new features and functionalities we have introduced over the past five years, including Invisalign G5 and G6, as well as SmartTrack material, have raised the bar for simple and comprehensive Clear Aligner treatments. While Invisalign Clear Aligners are already recognized as very credible orthodontic appliances, we will increasingly focus our efforts on creating doctor advocacy for Invisalign clinical competences.
產品創新仍是我們長期成長的核心,也是加速成人與青少年兩大區隔採用 Invisalign 治療的關鍵能力。過去五年我們導入的大量新功能與新特性,包括 Invisalign G5、G6 以及 SmartTrack 材料,已提高了簡單與全方位隱形矯正治療的標準。雖然 Invisalign 隱形矯正器已被公認為非常可信賴的矯正器材,我們將更進一步把重點放在建立醫師對 Invisalign 臨床能力的倡議與認同。
In Q3, our scanner and services business revenues were up sequentially from higher sales of iTero scanners. On a year-over-year basis, revenue was down as expected and in line with our guidance, as a result of the transition to the new iTero Element scanner. Since its introduction in March, interest and demand for the new iTero Element has been overwhelmingly positive. During the quarter, we completed the initial market release of the iTero Element orthodontic scanner with shipments starting in September. To date, over 2,000 Invisalign cases have been initiated with the new iTero Element.
在第三季,我們的掃描器與服務業務營收因 iTero 掃描器銷售增加而較前一季成長。以年對年來看,營收如預期且符合我們的指引而下滑,原因是轉換至新款 iTero Element 掃描器。自三月推出以來,市場對新款 iTero Element 的興趣與需求反應極為正面。本季期間,我們完成 iTero Element 矯正用掃描器的初期市場上市,並於九月開始出貨。截至目前,使用新款 iTero Element 已啟動超過 2,000 件 Invisalign 案例。
Customers tell us that the new design meets the high level of precision they expect from an iTero, with an Invisalign scan acceptance rate of 99.8%. We will expand the market release of our iTero Element to include restorative applications during Q4 this year.
客戶告訴我們,新設計符合他們對 iTero 一貫期待的高精準度,Invisalign 掃描接受率達 99.8%。我們將於今年第四季擴大 iTero Element 的市場上市範圍,納入修復(restorative)應用。
For Q3, total Invisalign cases submitted with a digital scanner in North America was 40.5%, up from 39% last quarter and 34% the same quarter last year.
第三季在北美,使用數位掃描器提交的 Invisalign 總案例占比為 40.5%,高於上一季的 39% 以及去年同期的 34%。
In North America, our integrated consumer marketing approach continues to be highly impactful, with Q3 consumer search interest for Invisalign treatment up 20% year over year. In addition, we had more than 1.3 million unique visitors to our invisalign.com website and more than 112,000 potential patients search for an Invisalign practice on our doc locator. Our multichannel marketing approach leverages national television, search, digital marketing, PR, and social media and is designed to engage consumers throughout every point in the consumer purchase journey.
在北美,我們整合式消費者行銷策略持續展現高度成效,第三季消費者對 Invisalign 治療的搜尋興趣年增 20%。此外,我們的 invisalign.com 網站有超過 130 萬名不重複訪客,且有超過 112,000 名潛在患者透過我們的醫師搜尋工具(doc locator)尋找 Invisalign 診所。我們的多通路行銷策略結合全國性電視、搜尋、數位行銷、公關與社群媒體,旨在於消費者購買旅程的每一個接觸點與其互動。
During Q3, we focused on reaching moms and teens during the key back-to-school season by continuing the Invisalign Teen Confidence campaign we launched in May. The campaign generated more than 385 million consumer impressions across 20 key markets and drove moms to the Invisalign.com parent page, with unique visits up 102% during the campaign period.
第三季期間,我們延續五月推出的「Invisalign Teen Confidence」活動,聚焦在關鍵的返校季以觸及媽媽與青少年。該活動在 20 個重點市場累計產生超過 3.85 億次消費者曝光,並帶動媽媽族群前往 Invisalign.com 的家長頁面,活動期間不重複造訪次數成長 102%。
In EMEA, our integrated consumer plan relies heavily on social media and online marketing in key markets. Even with the summer holidays across Europe and related seasonality, we saw great engagement with find-a-doctor searches increasing by 250% year over year and 200% growth in our EU social media community.
在 EMEA 地區,我們的整合式消費者計畫在重點市場高度仰賴社群媒體與線上行銷。即使歐洲正值暑期假期並伴隨季節性因素,我們仍看到良好互動,找醫師(find-a-doctor)搜尋量年增 250%,且我們的歐盟社群媒體社群規模成長 200%。
Before I turn the call over to David for a review of our financial performance, I want to comment on two recent litigation filings. This week, we dismissed a California state lawsuit originally filed against ClearCorrect in 2011. That suit alleged unlawful business practices regarding pricing and has no bearing on our outstanding patent infringement case against ClearCorrect through the International Trade Commission, ITC, who previously found ClearCorrect to infringe on our patent.
在我把電話會議交給 David 回顧我們的財務表現之前,我想評論兩起近期的訴訟案件。本週,我們撤回了加州州法院一宗於 2011 年最初對 ClearCorrect 提起的訴訟。該案指稱與定價相關的不法商業行為,且與我們目前在國際貿易委員會(ITC)對 ClearCorrect 提起、尚未結案的專利侵權案件無關;ITC 先前已認定 ClearCorrect 侵害我們的專利。
ClearCorrect also dismissed a related cross-claim against us in California.
ClearCorrect 也在加州撤回了對我們提出的相關反訴(cross-claim)。
In the area of litigation, today we announced that we have filed an infringement and false advertising lawsuit against SmileCareClub, Sharper Image, and Brickstone, companies involved in the sale of do-it-yourself at-home Clear Aligner products sold directly to consumers. The details related to our claims and specific patents in question are noted in the press release we issued.
在訴訟方面,我們今日宣布已對 SmileCareClub、Sharper Image 與 Brickstone 提起侵權及不實廣告訴訟;這些公司涉及銷售直接面向消費者的 DIY 居家透明矯正器產品。我們所主張的內容與涉及的特定專利細節,已載明於我們發布的新聞稿中。
However, it is worth mentioning here that while this is a new lawsuit, we believe ClearCorrect is treatment planning and manufacturing aligners for SmileCareClub using the same methods that the ITC previously found to infringe on Align's valid patents. We anticipate that additional information regarding this relationship will come to light during discovery.
不過值得在此一提的是,雖然這是一宗新訴訟,我們相信 ClearCorrect 正以 ITC 先前認定侵害 Align 有效專利的相同方法,為 SmileCareClub 進行治療規劃並製造矯正器。我們預期在證據開示(discovery)過程中,將有更多關於此關係的資訊浮現。
SmileCareClub not only markets and sells its aligners directly to consumers, it also supplies aligners to resellers, Sharper Image and Brickstone stores, who are named in the lawsuit as retailers of the SmileCareClub system. This situation is of particular concern in that it not only involves the marketing and sale of a product we believe infringes Align's patents, SmileCareClub also promotes a treatment option that seeks to eliminate the critical role played by the doctor in the patient's treatment.
SmileCareClub 不僅直接向消費者行銷並銷售其矯正器,也向經銷商供貨,包括 Sharper Image 與 Brickstone 門市;這些經銷商在本訴訟中被列為 SmileCareClub 系統的零售商。此情況特別令人關切,因為它不僅涉及我們認為侵害 Align 專利的產品之行銷與銷售,SmileCareClub 也在推廣一種治療選項,試圖排除醫師在患者治療中所扮演的關鍵角色。
Align has always believed that orthodontists and dentists play a critical role in successful orthodontic treatment using Clear Aligners, which is why the Invisalign system is so tightly integrated with the treating dental profession.
Align 一直相信,矯正專科醫師與牙醫在使用透明矯正器進行成功的矯正治療中扮演關鍵角色,這也是 Invisalign 系統與臨床牙科專業緊密整合的原因。
With over 640 patents worldwide, litigation is part of doing business as an innovative growth company, and we will continue to assert and defend our intellectual property rights. The ITC has already found that ClearCorrect's product infringes Align's valid patents and we are confident that the final outcome in both cases will be a win for Align.
我們在全球擁有超過 640 件專利,作為一家創新成長型公司,訴訟是經營的一部分;我們將持續主張並捍衛我們的智慧財產權。ITC 已認定 ClearCorrect 的產品侵害 Align 的有效專利,我們有信心兩起案件的最終結果都將對 Align 有利。
I will now turn the call over to David.
我現在把電話會議交給 David。
David White - CFO
David White - CFO
Thanks, Joe. Let's review our third-quarter financial results.
謝謝,Joe。讓我們回顧第三季的財務結果。
Revenue for the third quarter was $207.6 million, down 0.9% from the prior quarter and up 9.4% from the corresponding quarter a year ago. Third-quarter revenues included a non-cash reduction of approximately $7 million related to our new additional aligners policy announced last quarter.
第三季營收為 2.076 億美元,較前一季下滑 0.9%,較去年同期成長 9.4%。第三季營收包含約 700 萬美元的非現金(non-cash)減項,與我們上季宣布的新「追加矯正器」政策相關。
Third-quarter aligner revenue of $198.3 million was down 1.3% sequentially and up 11.3% year over year. The sequential revenue decrease was primarily related to our new additional aligners policy, as just mentioned.
第三季矯正器營收為 1.983 億美元,較前一季下滑 1.3%,較去年同期成長 11.3%。如前所述,營收的季對季下滑主要與新的追加矯正器政策相關。
Q3 ASPs were down sequentially about $45, which was almost entirely due to higher revenue deferrals from the new additional aligners policy. Excluding additional aligners, ASPs were otherwise flat quarter over quarter.
第三季 ASP(平均銷售價格)較前一季下降約 45 美元,幾乎完全是因新追加矯正器政策導致較高的營收遞延。排除追加矯正器因素後,ASP 其他部分則為季對季持平。
Our year-over-year revenue growth reflected Invisalign case volume growth across all customer channels, partially offset by lower ASPs primarily related to foreign-exchange rates and the higher revenue deferrals just mentioned.
我們的年對年營收成長反映 Invisalign 案例量在所有客戶通路皆成長,但部分被 ASP 較低所抵銷;ASP 下滑主要與外匯匯率以及前述較高的營收遞延相關。
For the third quarter, total Invisalign shipments of 147,500 cases were up 2.0% sequentially, reflecting growth from our North American orthodontic and international customers. Year over year, case volume growth was 23.3%, driven by growth across all regions, with strength in international and continued progress in North America.
第三季 Invisalign 總出貨量為 147,500 件案例,較前一季成長 2.0%,反映北美矯正專科與國際客戶的成長。年對年而言,案例量成長 23.3%,由各地區全面成長所帶動,其中國際市場表現強勁,北美也持續取得進展。
For North American orthodontists, Q3 Invisalign case volume was up 5.4% sequentially and up 21.4% year over year. For North American GP dentists, case volume was down 2.6% sequentially and up 15.3% year over year. For international doctors, Invisalign case volume was up 2.9% sequentially and 35.1% year over year.
就北美矯正專科醫師而言,第三季 Invisalign 案例量較前一季成長 5.4%,較去年同期成長 21.4%。就北美一般牙醫(GP)而言,案例量較前一季下滑 2.6%,較去年同期成長 15.3%。就國際醫師而言,Invisalign 案例量較前一季成長 2.9%,較去年同期成長 35.1%。
Worldwide Invisalign utilization in Q3 was 4.7 cases per doctor, up slightly from 4.4 in Q3 last year. North America ortho utilization of 9.9 was a new record, increasing from 8.8 in the prior year. North America GP utilization was 2.9, was up slightly from 2.8 in the prior year, and international doctor utilization of 4.6 was up slightly from 4.3 in the prior year.
第三季全球 Invisalign 使用率為每位醫師 4.7 件案例,較去年第三季的 4.4 略為上升。北美矯正專科使用率 9.9 創新高,較前一年之 8.8 提升。北美一般牙醫使用率為 2.9,較前一年之 2.8 略升;國際醫師使用率為 4.6,較前一年之 4.3 略升。
In Q3, we added 2,260 new Invisalign doctors worldwide, 1,060 of which were new North American doctors and 1,200 of which were new international doctors.
在第三季,我們在全球新增了 2,260 位新的 Invisalign 醫師,其中 1,060 位為北美新醫師,1,200 位為國際新醫師。
Q3 is seasonally a slower training quarter due to holidays and summer vacations, so the number of Invisalign doctors trained was down approximately 8% sequentially.
由於假期與暑期休假,第三季在季節性上是較慢的培訓季度,因此受訓的 Invisalign 醫師人數較前一季約下降 8%。
Our scanner and services revenues were up 7.8% sequentially and down 20.4% year over year, primarily as the result of the new iTero Element scanner, which didn't commence shipping until September.
我們的掃描儀與服務營收較前一季成長 7.8%,但較去年同期下降 20.4%,主要是因為新款 iTero Element 掃描儀直到 9 月才開始出貨。
Moving on to gross margin, third-quarter overall gross margin was 75.9%, up sequentially 0.2 points and down 0.5 points year over year. Clear Aligner gross margin for the third quarter was 78.8%, up 0.5 points sequentially and down 0.04 points year over year. The sequential increase was primarily driven by lower freight costs and seasonally lower training activity, which was only partially offset by the impact of the additional aligners policy.
接著談毛利率,第三季整體毛利率為 75.9%,較前一季上升 0.2 個百分點,較去年同期下降 0.5 個百分點。第三季透明牙套(Clear Aligner)毛利率為 78.8%,較前一季上升 0.5 個百分點,較去年同期下降 0.04 個百分點。前一季的上升主要由較低的運費成本與季節性較低的培訓活動所帶動,但部分被新增牙套政策的影響所抵銷。
The year-over-year decrease in gross margin was primarily the result of lower ASPs, primarily attributable to currency exchange rates and the new additional aligners policy, which were partially offset by lower manufacturing costs.
毛利率的年對年下降主要是由於平均售價(ASP)較低,主要歸因於匯率變動與新的新增牙套政策;但部分被較低的製造成本所抵銷。
Q3 gross margin for our scanner segment was 14.7%, down 0.3 points sequentially and down 18.8 points year over year, both as the result of lower ASP due to a closeout incentive pricing program on our older iTero 2.9 scanner and lower production volumes.
第三季我們掃描儀部門的毛利率為 14.7%,較前一季下降 0.3 個百分點,較去年同期下降 18.8 個百分點;兩者皆是由於我們較舊的 iTero 2.9 掃描儀採取清庫存激勵定價方案導致 ASP 較低,以及產量較低所致。
Q3 operating expenses were $119.5 million, up sequentially by $3.2 million primarily due to, first, increased investments to support our continued international growth and expansion and higher media spend; secondly, costs primarily associated with severance costs for organizational changes previously announced; and third, costs related to the termination of an agreement with a third-party company for product development in the obstructive sleep apnea area.
第三季營業費用為 1.195 億美元,較前一季增加 320 萬美元,主要原因包括:第一,為支持我們持續的國際成長與擴張而增加投資,以及媒體投放支出提高;第二,主要與先前宣布的組織調整相關的資遣費用;第三,與終止與第三方公司在阻塞型睡眠呼吸中止症(OSA)領域之產品開發協議相關的成本。
On this latter matter, while we continue to believe opportunities in the OSA market are potentially interesting, we have now decided to remain squarely focused on our core business and organic growth opportunities.
就後者而言,雖然我們仍認為 OSA 市場的機會可能具有吸引力,但我們現已決定將重心明確放在核心業務與內生成長機會上。
On a year-over-year basis, Q3 operating expenses were up $26 million, incidental to the growth of the business, as well as our ERP implementation project.
以年對年來看,第三季營業費用增加 2,600 萬美元,主要是隨著業務成長所致,以及我們的 ERP 導入專案。
Our third-quarter operating margin was 18.3%, down 1.9 points sequentially and down 8.8 points year over year. The sequential decrease in operating margin relates primarily to the impact on revenue of the new additional aligners policy, which amounted to 2.6 points, partially offset by lower manufacturing costs. The year-over-year impact relates primarily to these factors, as well as foreign-currency exchange rates and investments in the business related to sales expansion, R&D, and ERP.
第三季營業利益率為 18.3%,較前一季下降 1.9 個百分點,較去年同期下降 8.8 個百分點。營業利益率的前一季下降主要與新的新增牙套政策對營收的影響有關,影響幅度為 2.6 個百分點,部分被較低的製造成本所抵銷。年對年的影響主要也與上述因素相關,並包含外匯匯率,以及與銷售擴張、研發與 ERP 相關的業務投資。
With regards to our third-quarter tax provision, our tax rate was 24.3%, down 1.9 points from our Q2 tax rate. This is primarily due to a tax benefit as a result of the filing of our US federal tax return this quarter.
關於第三季所得稅費用,我們的有效稅率為 24.3%,較第二季稅率下降 1.9 個百分點。這主要是因本季申報美國聯邦所得稅申報表而產生的稅務利益。
Third-quarter diluted earnings per share was $0.34, compared to $0.39 reported in Q2 and $0.47 reported in the same quarter last year. Third-quarter EPS was impacted by approximately $0.06 related to the Company's new additional aligners policy. Further, the year-over-year impact from foreign exchange as a result of the stronger US dollars, including the decline on revenues, the benefit on our non-US dollar operating expenses, together with currency-exchange losses reported in other income and expense, was $0.04 per share.
第三季稀釋後每股盈餘為 0.34 美元,相較第二季為 0.39 美元、去年同期為 0.47 美元。第三季每股盈餘約受到公司新的新增牙套政策影響 0.06 美元。此外,由於美元走強所造成的外匯年對年影響(包括營收下降、非美元營業費用的利益,以及在其他收益與費用中認列的匯兌損失)為每股 0.04 美元。
Moving on to the balance sheet, capital expenditures for the third quarter were $10.5 million, primarily related to added equipment capacity to our second manufacturing facility in Juarez, Mexico, as well as additional costs capitalized on our ERP project. Cash flow from operations for the third quarter was $60.1 million and free cash flow for the third quarter, defined as cash flow from operations, less capital expenditures, amounted to $49.6 million.
接著看資產負債表,第三季資本支出為 1,050 萬美元,主要與墨西哥華雷斯(Juarez)第二座製造廠新增設備產能有關,以及 ERP 專案資本化的額外成本。第三季營運活動現金流為 6,010 萬美元;第三季自由現金流(定義為營運活動現金流減資本支出)為 4,960 萬美元。
As a side note, on a trailing 12-month basis our free cash flow as a percentage of revenue was 22.7%, consistent with our long-term model target of 20% to 25%.
補充說明,以過去 12 個月計算,我們的自由現金流占營收比重為 22.7%,符合我們長期模型目標的 20% 至 25%。
During the third quarter, we repurchased 662,000 shares of stock, including 332,000 shares related to the completion of the Company's previously announced $70 million accelerated stock repurchase and 330,000 shares amounting to $18.8 million in open market repurchases. As another side note, our last 12 months of stock repurchases, together with cash used to pay employee taxes for the net settlement of vesting employee stock that otherwise would have been issued, amounted to 71% of our worldwide free cash flow. We believe our free cash flow generation and these repurchases are consistent with our expressed capital allocation objectives of returning cash flow in excess of that needed to run and grow the business to our shareholders.
第三季期間,我們回購了 662,000 股股票,其中包括 332,000 股與完成公司先前宣布的 7,000 萬美元加速股票回購(ASR)相關,以及 330,000 股為公開市場回購,金額合計 1,880 萬美元。再補充一點,我們過去 12 個月的股票回購,加上用於支付員工稅款以進行已歸屬員工股票的淨額交割(原本將會發行)的現金,合計相當於我們全球自由現金流的 71%。我們相信,我們的自由現金流創造能力與這些回購,符合我們所表達的資本配置目標:將超出維持與成長業務所需的現金流回饋給股東。
Cash, cash equivalents, and marketable securities, including both short- and long-term investments, were $630 million. This compared to $602.6 million at the end of 2014, an increase of approximately $27.4 million. Of our $630 million of cash, cash equivalents, and marketable securities, $213 million was held by the US and $417 million held by our international entities.
現金、約當現金與有價證券(包含短期與長期投資)為 6.30 億美元。相較 2014 年底的 6.026 億美元,約增加 2,740 萬美元。在 6.30 億美元的現金、約當現金與有價證券中,2.13 億美元由美國持有,4.17 億美元由國際實體持有。
With that, let's now turn to our business outlook for the fourth quarter and the factors that inform our view, starting with the demand outlook. For North America, we are encouraged by continued progress in North America, with Q3 volume growth rates above our three-year average. While we continue to gain share in the important teen segment, the fourth quarter has historically been a seasonally slower quarter for ortho teen case starts. Notwithstanding this seasonal pattern, we expect North American Invisalign case volume to be up sequentially from Q3.
接下來,我們轉向第四季的業務展望,以及支撐我們觀點的因素,先從需求展望談起。就北美而言,我們對北美持續的進展感到鼓舞,第三季的量成長率高於我們三年平均。雖然我們在重要的青少年(teen)族群持續提升市占,但第四季在歷史上是矯正青少年病例啟動(case starts)季節性較慢的季度。儘管有此季節性型態,我們預期北美 Invisalign 病例量將較第三季呈現季增。
For international, Q4 has historically been a seasonally stronger quarter for EMEA and a seasonally slower to flat quarter for APAC. In total, we expect international volumes to also be up sequentially from Q3.
就國際市場而言,第四季在歷史上對 EMEA 來說是季節性較強的季度,對 APAC 則是季節性較慢至持平的季度。整體而言,我們預期國際量也將較第三季季增。
As a reminder, the changes of our new -- for the new additional aligners policy applied to all new Invisalign Full, Teen, and Assist products, our full product group, shipped worldwide after July 18, 2015, as well as any such open cases started prior to this product policy change. As a result, beginning in Q3 our deferrals increased as a result of providing these additional aligners at no charge and the grandfathering of over 1 million open cases.
提醒一下,我們新的新增牙套政策之變更適用於 2015 年 7 月 18 日之後在全球出貨的所有新 Invisalign Full、Teen 與 Assist 產品(我們的完整產品群),以及在此產品政策變更前已開始的任何此類未結案病例。因此,自第三季起,由於免費提供這些新增牙套,以及對超過 100 萬件未結案病例採取既有條款(grandfathering),我們的遞延金額增加。
The effect on our future revenue is twofold. The first is an increase in the amount we defer for each new case we ship. The second impact is that revenue recognized on each additional aligners shipment will be lower than the amounts we have historically recognized until these grandfathered cases are completed, which we anticipate will take approximately two years.
對我們未來營收的影響有兩個面向。第一,是我們對每一個出貨的新病例所遞延的金額增加。第二個影響是,在這些既有條款適用的病例結案之前,每次新增牙套出貨所認列的營收將低於我們過去歷來認列的金額;我們預期完成這些既有條款病例約需兩年時間。
As a result of this policy change, we expect Q4 2015 to be lower than it otherwise would have been by approximately $7 million to $8 million. This is consistent with the guidance we gave in our Q2 earnings call.
由於這項政策變更,我們預期2015年第四季將較原本可能達到的水準低約700萬至800萬美元。這與我們在第二季財報電話會議中提供的指引一致。
For 2016, we expect this impact to be between $25 million and $30 million in total. Relative to our historical growth rates, we believe the current-year Clear Aligner volume growth will more than offset this impact on future revenues.
對於2016年,我們預期此影響合計將介於2,500萬至3,000萬美元之間。相較於我們的歷史成長率,我們相信本年度Clear Aligner的出貨量成長將足以抵銷此對未來營收的影響,且幅度更大。
With this as a backdrop, we expect the fourth quarter to shape up as follows. Invisalign case volume is anticipated to be in the range of 154,900 to 157,400 cases, up approximately 22% to 24% over the same period a year ago. We expect Q4 net revenues to be in the range of $223 million to $227.9 million.
在此背景下,我們預期第四季將如下發展。Invisalign病例量預計介於154,900至157,400例,較去年同期約成長22%至24%。我們預期第四季淨營收將介於2.23億至2.279億美元。
We expect gross margin to be in the range of 75.7% to 76.2%. We expect operating expenses to be in the range of $114.7 million to $116.3 million. Our operating margin should be in the range of 24.3% to 25.1%.
我們預期毛利率將介於75.7%至76.2%。我們預期營業費用將介於1.147億至1.163億美元。我們的營業利益率應介於24.3%至25.1%。
Our effective tax rate should be approximately 24.5%. And diluted shares outstanding should be approximately 81.4 million, exclusive of any share repurchases.
我們的有效稅率應約為24.5%。稀釋後流通在外股數應約為8,140萬股,不含任何庫藏股回購。
Taken together, we expect diluted EPS to be in the range of $0.50 to $0.53.
綜合以上,我們預期稀釋後每股盈餘(EPS)將介於0.50至0.53美元。
With that, I will turn the call back over to Joe.
接下來,我把電話交回給Joe。
Joe Hogan - President, CEO
Joe Hogan - President, CEO
Thanks, David.
謝謝,David。
I am pleased with our Q3 results, which reflect stable patient traffic in our customers' offices and their confidence in using Invisalign on more patients and on more complex cases. Our goal is to be the best partner by providing great treatment experiences for our doctors and their patients.
我對我們第三季的結果感到滿意,這反映出我們客戶診所的病患來診量穩定,以及他們對於在更多病患、以及更複雜病例上使用Invisalign的信心。我們的目標是成為最佳合作夥伴,為醫師及其病患提供優異的治療體驗。
Overall, we continue to see good momentum across our customers' channels and believe our investments in sales, marketing, and R&D are helping to drive growth.
整體而言,我們持續在各客戶通路看到良好動能,並相信我們在銷售、行銷與研發方面的投資正有助於推動成長。
Thank you for your time today. I look forward to updating you on our progress. With that, we will open up the call to your questions. Operator?
感謝各位今天撥冗參與。我期待向各位更新我們的進展。接下來,我們將開放提問。接線員?
Operator
Operator
(Operator Instructions). Robert Jones, Goldman Sachs.
(接線員指示)。Robert Jones,高盛。
Nathan Rich - Analyst
Nathan Rich - Analyst
This is Nathan Rich on for Bob this afternoon. A couple questions on guidance. First, it looks like guidance implies that ASPs will be up sequentially in the fourth quarter versus the third, if I'm doing that math right. Just wondering if you could give us some more details on your expectations for both North America and international ASPs. I think there are a decent amount of moving pieces just with the revenue recognition change, FX, and case mix.
各位下午好,我是代替Bob的Nathan Rich。我有幾個關於指引的問題。首先,如果我計算無誤,看起來指引意味著第四季的ASP將較第三季呈現季增。想請問你們能否提供更多關於北美與國際ASP預期的細節。我認為在收入認列變更、匯率(FX)以及病例組合等因素下,變動因素相當多。
David White - CFO
David White - CFO
Hi, Nathan. It is David. Thanks for the question.
嗨,Nathan。我是David。謝謝你的提問。
As it relates to ASPs in the fourth quarter and the outlook as it relates there, too, we are expecting a modest increase in ASPs in Q4, not actually that substantial, primarily due to less -- fewer promotions we run in Q4 versus what we typically do in third quarter.
就第四季的ASP以及相關展望而言,我們預期第四季ASP會小幅上升,實際上不會大幅變動,主要原因是第四季我們進行的促銷活動較少——相較於我們通常在第三季所做的。
The other piece of it is that we implemented a price increase internationally in July and it takes a while for that price increase to work its way through work in process and cases that are in various stages of submission. And so, we only got a partial benefit of that last quarter. We expect to get full benefit of that this quarter.
另一個因素是,我們在7月於國際市場實施了漲價,而這需要一些時間,讓漲價效應在製程中的訂單以及處於不同提交階段的病例中逐步反映出來。因此,上季我們只獲得了部分效益。我們預期本季將能獲得完整效益。
So, those are the two things factoring from a positive standpoint. There is a little bit of FX headwind, but not very much. But a little bit positive on the ASP.
所以,以上兩點是正向因素。匯率方面有些許逆風,但不算太大。整體而言,ASP會略為正向。
Nathan Rich - Analyst
Nathan Rich - Analyst
Okay, it makes sense.
好的,了解。
And then, if I could just ask on the operating-margin guidance as well, it looks like for the fourth quarter you are expecting a pretty big step-up in EBIT margins. Just wanted to get your sense of how much visibility you feel like you have here. Is it just a factor of leveraging higher sales volumes, and maybe could you talk about the productivity of the sales people that you have brought on and how you feel about that return on investment?
另外,若我也能問一下營業利益率指引:看起來你們預期第四季EBIT利潤率會有相當大的跳升。想了解你們對此有多大的能見度。這是否只是更高銷售量帶來的規模效益?另外,你們是否能談談新招募的銷售人員的生產力,以及你們對該投資報酬的看法?
David White - CFO
David White - CFO
So, possibly two questions there. As it relates to operating margin, our Q4 visibility -- if you drill down a little bit into it, you'll see that our guidance for gross margin is pretty consistent with our actual results in Q3. And where the uplift really in operating margin in Q4 comes from is the fact that our operating expenses are going down slightly quarter over quarter on higher revenue.
這裡可能有兩個問題。就營業利益率而言,我們對第四季的能見度——如果你再深入看一下,會發現我們對毛利率的指引與第三季的實際結果相當一致。而第四季營業利益率提升的主要來源,是在營收更高的情況下,我們的營業費用較上季略為下降。
And so, that is the principal driver. I think that's about 9 points of the operating margin increase quarter over quarter is that factor right there.
因此,這是主要驅動因素。我認為營業利益率季對季增加中,大約有9個百分點就是來自這個因素。
Nathan Rich - Analyst
Nathan Rich - Analyst
Great. Thank you.
很好。謝謝。
Operator
Operator
Steve Beuchaw, Morgan Stanley.
Steve Beuchaw,摩根士丹利。
Steve Beuchaw - Analyst
Steve Beuchaw - Analyst
Thanks for taking the questions. So I will ask two, one for Joe and then -- sorry, is Roger on the call as well?
謝謝讓我提問。我會問兩個問題,一個給Joe,然後——抱歉,Roger也在線上嗎?
Shirley Stacy - VP Corporate Communications & IR
Shirley Stacy - VP Corporate Communications & IR
Yes.
是的。
Steve Beuchaw - Analyst
Steve Beuchaw - Analyst
Okay, so first for Joe. So, Joe, could you take a step back and just talk about the volumes and maybe rank order what the drivers are? If you take a step back and say, we have growth that is materially above 20%, but you listed off quite a few items that the Company did well during the quarter, but if you had to look at one or two things and say, look, this is really what has sequentially come on and made the business grow faster here in 2015, what would those one or two things be and how do you see those evolving from here?
好的,那先問Joe。Joe,你能否退一步,談談出貨量(volumes),並且或許按重要性排序一下主要驅動因素?如果退一步看,我們的成長率明顯高於20%,你也列舉了公司在本季做得很好的不少事項;但如果你必須挑出一到兩件事,說明究竟是什麼在2015年讓業務在序列上加速成長,那會是哪一到兩件?你又如何看待它們接下來的演變?
Joe Hogan - President, CEO
Joe Hogan - President, CEO
I think versus last year is -- first of all, you have to look at North America. It is the strongest comparison that we have year over year because they did have a poor 2014. And so, and it is if you look at -- the growth has been there. The orthodontics sector has been terrific for us. You can see we have a penetration rate there that is a record at 9.9, and so that's very significant.
我認為相較去年——首先,你必須看北美市場。因為北美的年對年比較是我們最強的對比,原因是他們在2014年的表現確實較弱。因此,如果你看——成長一直都在。矯正(orthodontics)領域對我們而言表現非常出色。你可以看到我們在那裡的滲透率創下紀錄,達到9.9,這非常重要。
We are seeing growth again in the GP area and double-digit growth that we hadn't experienced in North America prior to that in the few previous years. So I think, overall, that's probably one of the biggest variants, I would say, year to year.
我們也再次看到GP(一般牙科)領域的成長,且在北美出現了過去幾年未曾有過的雙位數成長。所以我認為,整體而言,這大概是年對年最大的差異之一。
What we have had from a continuous standpoint is you can see the terrific growth we have going on in EMEA right now, in Europe, and also the continued growth that we have in APAC also, which is very strong. So that is continued momentum and it is also on top of some pretty strong numbers from last year, so I think those four variables, I would say, Steve, overall are the big drivers.
從持續性的角度來看,你也可以看到我們目前在EMEA(歐洲、中東與非洲)地區、也就是歐洲的成長非常亮眼,此外我們在APAC(亞太)也持續成長,且非常強勁。因此,這是持續的動能,而且是在去年相當強勁的基期之上所達成的;所以我想,Steve,整體而言我會說這四個變數是主要驅動因素。
Steve Beuchaw - Analyst
Steve Beuchaw - Analyst
You haven't been, I would say, wildly optimistic about GP. Do you think the double-digit growth in GP is sustainable in North America?
你對於 GP 我會說,一直都不是非常樂觀。你認為在北美 GP 的兩位數成長是否具有可持續性?
Joe Hogan - President, CEO
Joe Hogan - President, CEO
I think there is an aspect of GP that -- we don't go deep in GP right now; we go wide. So you can see we have about 2.9 or 3 cases per GP unit versus 9.9 on ortho. As we add salespeople, we know we'd get more sales in GP.
我認為 GP 有一個面向是——我們目前在 GP 上並沒有做深;我們做的是做廣。所以你可以看到,我們每個 GP 單位大約有 2.9 或 3 個病例,相較之下,矯正(ortho)是 9.9。隨著我們增加業務人員,我們知道在 GP 會帶來更多銷售。
What we have to work on and I think what you said -- I don't -- haven't talked about that a lot; I'm not enthusiastic about it, I think what your words were. I am; it's just we have to do better at penetration in that segment and that's what we really have to work on.
我們必須努力的地方,而且我想你剛才說的——我——我沒有談很多;我對此不熱衷,我想你用的詞是這樣。我其實是熱衷的;只是我們必須在那個細分領域做得更好、提高滲透率,而這正是我們真正需要努力的。
Steve Beuchaw - Analyst
Steve Beuchaw - Analyst
Okay, and then just one for Roger. I think -- well, first of all, welcome back to the call, Roger.
好的,接著給 Roger 一個問題。我想——嗯,首先,歡迎回到電話會議,Roger。
Roger George - VP Legal Affairs, General Counsel
Roger George - VP Legal Affairs, General Counsel
Thanks, Steve.
謝謝,Steve。
Steve Beuchaw - Analyst
Steve Beuchaw - Analyst
I know this is your favorite part of the job. The SmileCareClub litigation was, I guess, a little surprising. How big are they right now? Are they even 2% or 3% of the market? And I guess while we're on the legal topic, what do you think the timelines could be as it relates to some enforcement around ClearCorrect?
我知道這是你工作中最喜歡的部分。SmileCareClub 的訴訟我想有點令人意外。他們目前規模有多大?他們甚至有到市場的 2% 或 3% 嗎?另外既然談到法律議題,你認為就 ClearCorrect 相關的一些執法行動,時間表可能會是怎樣?
Roger George - VP Legal Affairs, General Counsel
Roger George - VP Legal Affairs, General Counsel
Sure, so as far as the market size of SmileCareClub, it is negligible. We don't see them that much out there.
當然。就 SmileCareClub 的市場規模而言,幾乎可以忽略不計。我們在市場上並沒有太常看到他們。
As far as timing on ClearCorrect, the case was -- the case at the ITC was appealed up through the federal courts, most recently at the Federal Circuit Court of Appeals, and oral arguments were held in August and we expect a written decision from the court sometime in the first quarter of next year.
至於 ClearCorrect 的時程,該案——在 ITC 的案件已一路上訴到聯邦法院,最近是在聯邦巡迴上訴法院,並且已於 8 月進行口頭辯論;我們預期法院會在明年第一季的某個時間做出書面裁決。
Steve Beuchaw - Analyst
Steve Beuchaw - Analyst
Great. Thanks so much, everyone.
太好了。非常感謝各位。
Operator
Operator
John Kreger, William Blair.
John Kreger,William Blair。
John Kreger - Analyst
John Kreger - Analyst
Joe, just to follow up on the last question about key growth drivers, what is your assessment about the underlying market growth, particularly for orthodontists? Would you characterize it as stable or are you seeing any improvement there?
Joe,延續上一題關於主要成長動能的問題,你對於基礎市場成長、特別是針對矯正醫師(orthodontists)的看法是什麼?你會形容它是穩定的,還是你看到有任何改善?
Joe Hogan - President, CEO
Joe Hogan - President, CEO
You mean from a market overall, John, you mean outside of us or just the market itself?
John,你是指整體市場的角度嗎?你是指我們以外的情況,還是單純指市場本身?
John Kreger - Analyst
John Kreger - Analyst
Yes, so, in other words, looking at that 23% case growth, how much of that, if any, do you think is market?
是的,也就是說,看那 23% 的病例成長,其中有多少(如果有的話)你認為是市場帶來的?
Joe Hogan - President, CEO
Joe Hogan - President, CEO
I think we have a favorable market behind us, John, is the way that I would answer that question. We don't have a down market behind us, and that kind of market momentum is really helpful.
John,我會這樣回答:我們背後有一個有利的市場環境。我們背後不是一個下行的市場,而那種市場動能確實很有幫助。
To tell you how many points of growth that I think have to do with the market itself versus what we are driving from a penetration standpoint, I really don't have that kind of information. So I can't give you the specifics like that. But it is -- it is beneficial to have a market that is growing behind you.
至於我認為成長中有多少個百分點是來自市場本身、相對於我們從滲透率角度所推動的,我真的沒有那類資訊。所以我無法給你那樣的具體拆分。但——有一個成長中的市場作為後盾確實是有利的。
David White - CFO
David White - CFO
And typically, John, as you know, the industry has typically grown in low single digits, and so nothing substantial has changed from that standpoint.
而且通常,John,如你所知,這個產業一般是以低個位數成長,所以從這個角度看並沒有什麼實質性的改變。
John Kreger - Analyst
John Kreger - Analyst
Great, okay. And Joe, as you have had a bit more time to kick the tires, so to speak, around the world, can you maybe comment on what your priorities are going to be over the next year?
很好,了解。另外,Joe,既然你有更多時間(可以說是)到全球各地實地了解,你能否談談你接下來一年會有哪些優先事項?
Joe Hogan - President, CEO
Joe Hogan - President, CEO
Priorities is obviously growth and profitability overall for the Company. From a growth standpoint, John, and staying on your original question, the international part is a big part of our growth and you're going to see us continue to invest heavily in that area to drive the growth that we think we can get there.
優先事項顯然是公司整體的成長與獲利能力。就成長而言,John,回到你原本的問題,國際市場是我們成長的一大部分;你會看到我們持續在那個領域大力投資,以推動我們認為能在那裡取得的成長。
But that doesn't mean we will negate North America. North America is a big market. There is a law of large number issue on North America. We report lower percentages, but when you look at case volumes, they can be fairly close together. And so, you'll see us continue to invest pretty aggressively from a distribution standpoint in all three regions.
但這不代表我們會忽視北美。北美是一個很大的市場。北美存在「大數法則」的問題。我們呈現的百分比會比較低,但當你看病例量時,彼此可能相當接近。因此,你會看到我們在三大區域的通路/分銷面仍會持續相當積極地投資。
John Kreger - Analyst
John Kreger - Analyst
Okay, thanks. And then one last one, now that you have had a few months to assess how clients are viewing the new policy about not charging for additional aligner refinements, how is that impacting client behavior, if at all, and are there key regions where that has been a bigger driver than others?
好的,謝謝。最後一題:現在你已經有幾個月時間評估客戶如何看待「不再對額外的隱形牙套精修(refinements)收費」這項新政策,這對客戶行為是否有任何影響?如果有,是否有某些地區的帶動效果比其他地區更大?
Joe Hogan - President, CEO
Joe Hogan - President, CEO
I think you could -- you can ask that question in two ways, John. Is it a negative driver in the sense we see people trying to maybe take advantage of the policy, and then the other side of it is how comfortable does it make our customer base?
John,我想你可以用兩種方式來問這個問題。一種是它是否成為負面驅動因素,也就是我們是否看到有人試圖利用這項政策;另一種則是它讓我們的客戶群感到多安心。
We haven't seen any variant that would say that this is being abused in some way. And really, I have been personally amazed at the number of comments I get really all over the world on that change, and there is no question it is exactly the way the team represented it before I got here is that this was the number one biggest attractor that we had in the marketplace, regarding our product and our policies.
我們沒有看到任何跡象顯示這項政策以某種方式被濫用。而且老實說,我個人一直對於世界各地針對這項改變給我的回饋數量感到驚訝;毫無疑問,正如我來之前團隊所描述的,這是我們在市場上、就產品與政策而言,最重要、最大的吸引力。
I will give you an example. We talked about in our script about the Spain program that we had this year and that we just got back from. I had several doctors come up to me and just say, you know, Joe, it really increases my clinical competence to have this policy change. And they said because we feel like you have our back if we run into an issue with something that is a difficult case in some way, we don't feel like we're stranded.
我舉個例子。我們在講稿中提到今年在西班牙的專案,我們也才剛從那裡回來。有好幾位醫師走過來對我說,你知道嗎,Joe,這項政策改變真的提升了我的臨床勝任能力。他們說,因為我們覺得如果遇到某個困難病例的問題,你們會支持我們,我們不會覺得被丟在一旁。
And I never thought that would be one of the side effects or secondary effects on making that kind of a change. So, it has been overwhelmingly received in a very positive way. And I think some of the surveys that I know you guys do and that I read, you can see that a lot of the dentists that are surveyed on this will tell you that they feel happy about that and they will be more aggressive about using Invisalign in the future. And that was the purpose of what we did.
我從沒想過做出這樣的改變,會帶來這種副作用或次級效果。所以,它幾乎是以非常正面的方式被壓倒性地接受。而且我想從一些我知道你們會做、我也讀過的調查中,你可以看到許多受訪牙醫會告訴你,他們對此感到滿意,未來也會更積極使用 Invisalign。這就是我們這麼做的目的。
John Kreger - Analyst
John Kreger - Analyst
Great, thank you.
很好,謝謝你。
Operator
Operator
Richard Newitter, Leerink Partners.
Richard Newitter,Leerink Partners。
Ravi Misra - Analyst
Ravi Misra - Analyst
This is Ravi actually in for Rich. Thank you for taking the questions. I actually had one follow-up on some of the doctor -- the comments you had made about GP adoption. Just curious in terms of it sounds like you expect GP year-over-year growth to continue in that double-digit range. In terms of the doctors that you guys trained in the quarter, do you give any breakout in terms of how many of those are GPs versus orthodontics? (multiple speakers)
其實我是 Ravi,代替 Rich。謝謝讓我提問。我有一個追問,關於你對 GP 採用的一些醫師——評論。我好奇的是,聽起來你預期 GP 的年增成長會持續維持在兩位數區間。就你們本季訓練的醫師而言,你們是否能拆分其中有多少是 GP、多少是矯正科?(多位講者)
Joe Hogan - President, CEO
Joe Hogan - President, CEO
We do have data that tell you how many. I think, David (multiple speakers)
我們確實有數據可以告訴你有多少。我想,David(多位發言者)
David White - CFO
David White - CFO
I think if you look at the website slides, we probably break it out (multiple speakers)
我想如果你看網站上的簡報投影片,我們大概有把它拆分出來(多位發言者)
Ravi Misra - Analyst
Ravi Misra - Analyst
And is that number like new doctors (multiple speakers)
那個數字是像新醫師的人數嗎(多位發言者)
David White - CFO
David White - CFO
We normally provide that.
我們通常會提供那個。
Shirley Stacy - VP Corporate Communications & IR
Shirley Stacy - VP Corporate Communications & IR
North America total.
北美合計。
David White - CFO
David White - CFO
North America total.
北美合計。
Shirley Stacy - VP Corporate Communications & IR
Shirley Stacy - VP Corporate Communications & IR
Yes, total (multiple speakers)
是的,合計(多位發言者)
Ravi Misra - Analyst
Ravi Misra - Analyst
Yes, but that doesn't break down the (multiple speakers)
是的,但那沒有把……拆分(多位發言者)
Shirley Stacy - VP Corporate Communications & IR
Shirley Stacy - VP Corporate Communications & IR
Most of the doctors we train are GPs, right, so if you guys (multiple speakers) call historically and you can probably look at some of the historical data that we used to provide, but most of the doctors in North America are GPs.
我們訓練的大多數醫師是一般牙醫(GP),對吧,所以如果你們(多位發言者)回頭看歷史資料,你們大概可以看到我們以前提供過的一些歷史數據,但北美的大多數醫師都是一般牙醫(GP)。
Ravi Misra - Analyst
Ravi Misra - Analyst
And is that level increasing historically or is it still -- it is most and that's what we should expect going forward?
那這個比例在歷史上是上升的,還是仍然——就是大多數,而且我們未來也應該預期會是這樣?
Shirley Stacy - VP Corporate Communications & IR
Shirley Stacy - VP Corporate Communications & IR
Yes, you should expect that going forward most of the doctors we train will be GPs.
是的,你應該預期未來我們訓練的大多數醫師都會是一般牙醫(GP)。
David White - CFO
David White - CFO
In the North America.
在北美。
Shirley Stacy - VP Corporate Communications & IR
Shirley Stacy - VP Corporate Communications & IR
Yes, in North America.
是的,在北美。
Ravi Misra - Analyst
Ravi Misra - Analyst
Great, thanks. And then, maybe one on the litigation. Is there any read-through on this California dismissal with ITC that both you guys have now dismissed that lawsuit against one another to a potential settlement with the ITC litigation?
很好,謝謝。然後,可能再問一個關於訴訟的問題。你們在加州的撤訴(與 ITC 相關)是否有任何可解讀之處——也就是你們雙方現在都撤回彼此的訴訟——是否意味著 ITC 訴訟可能會達成和解?
Roger George - VP Legal Affairs, General Counsel
Roger George - VP Legal Affairs, General Counsel
Can you repeat that? I didn't hear the first part of it.
你可以再說一次嗎?我沒有聽到前半段。
Ravi Misra - Analyst
Ravi Misra - Analyst
Should we take the dismissal of the litigation in California by both parties as any sort of indication that there could be a settlement, or are you just -- should we just assume that you're willing to hear the ITC case play out?
我們是否應該把雙方在加州撤回訴訟,視為可能和解的某種訊號?還是——我們應該就假設你們願意讓 ITC 案件照程序走完?
Roger George - VP Legal Affairs, General Counsel
Roger George - VP Legal Affairs, General Counsel
You should not assume there will be a settlement.
你不應該假設會有和解。
Ravi Misra - Analyst
Ravi Misra - Analyst
Okay, great. And then, maybe one more on the scanners business. This came in a little bit lower than we had expected. Any sort of -- was that just seasonality or are you seeing any sort of capital challenges in that business there?
好的,很好。然後,可能再問一個關於掃描儀業務的問題。這部分的表現比我們預期略低。這是單純季節性因素,還是你們在那塊業務看到任何資本面(資本支出/資金)方面的挑戰?
David White - CFO
David White - CFO
So on the scanner business, it really has little to do, I think, with seasonality and everything to do with the cycle we are at in terms of transitioning from our historical scanner, which we call 2.9, to our new scanner called Element.
關於掃描儀業務,我認為這其實跟季節性關係不大,而是完全取決於我們目前所處的轉換週期:從我們過去的掃描儀(我們稱為 2.9)轉換到我們的新掃描儀 Element。
And we began shipping that product in September, and up until that point in time, we had been winding down the sale of the older 2.9. So it's more a function of that than anything else.
我們在 9 月開始出貨該產品,而在那之前,我們一直在逐步降低舊款 2.9 的銷售。所以這更多是那個因素造成的,而不是其他原因。
Ravi Misra - Analyst
Ravi Misra - Analyst
Got it. Thank you very much.
了解。非常感謝。
Operator
Operator
(Operator Instructions). Jeff Johnson, Robert W. Baird.
(接線員指示)。Jeff Johnson,Robert W. Baird。
Jeff Johnson - Analyst
Jeff Johnson - Analyst
Joe, I wanted to start with you, maybe. Strong fourth-quarter guidance on the case shipments, so I think I know the answer to this already. But are you seeing any fade at all in China from a demand standpoint? In the US, a little concern that maybe we started to see a consumer softening in the September time period in that. Are you seeing anything in your month-to-month numbers that would worry you, either China or the US, at this point?
Joe,我想先從你開始問。第四季對病例出貨量的指引很強,所以我想我大概已經知道答案了。但從需求角度來看,你們在中國有看到任何走弱嗎?在美國,有點擔心我們可能在 9 月期間開始看到消費者轉弱。就你們逐月的數據來看,目前中國或美國有任何會讓你擔心的跡象嗎?
Joe Hogan - President, CEO
Joe Hogan - President, CEO
The quick answer, Jeff, is no. China continues to be very strong. We had a good, strong September here in North America, too.
Jeff,簡短回答是沒有。中國仍然非常強勁。我們在北美這邊 9 月也表現得很好、很強。
I understand the basis of your question. I worry about it, too, is what is the economic activity going on in those particular areas. But right now, I'm not seeing any effect on the business in that sense.
我理解你這個問題的出發點。我也會擔心,因為要看那些地區的經濟活動狀況如何。但就目前而言,我沒有看到對業務造成任何影響。
Jeff Johnson - Analyst
Jeff Johnson - Analyst
Yes, that's what your guidance would imply, too, so thanks.
是的,你們的指引也暗示了同樣的情況,謝謝。
And then, David, maybe just a clarifying question for you on the additional aligner policy. I'm going back to my notes here, but the guidance you gave for the revenue impact in 2016, the 25 to 30, that's the total revenue drag from that policy in 2016 versus what looks like is now going to be a $13 million or $14 million drag in 2015. So the incremental drag, if you will, is only about $12 million to $15 million. Is that the way to think about it?
然後,David,可能再請你澄清一下額外牙套(additional aligner)政策。我回頭看我的筆記,你對 2016 年營收影響的指引是 2,500 萬到 3,000 萬,那是指 2016 年相對於原本情況、由該政策造成的總營收減少;而 2015 年看起來會是 1,300 萬或 1,400 萬的減少。所以增量的減少(如果這樣說)大概只有 1,200 萬到 1,500 萬。這樣理解對嗎?
David White - CFO
David White - CFO
That's correct and that's primarily because it is only a six-month drag on 2015.
沒錯,主要是因為 2015 年只會影響六個月。
Jeff Johnson - Analyst
Jeff Johnson - Analyst
Yes, yes, fair enough. I just wanted to make sure.
是的,是的,合理。我只是想確認一下。
And then my last question, just I guess with Roger there, I will ask him, but I thought I remembered, guys, that with the ClearCorrect ITC ruling, that even in appeals they could be risking some hefty day-to-day fines if they were still digitally treatment planning. So wondering, one, am I right on that? And two, does that mean anything in conjunction with what you said about them potentially treatment planning the SmileCareClub cases and just wondering if there is any impact, potential risk there, from that standpoint for them?
然後最後一個問題,我想既然 Roger 在,我就問他。不過各位,我記得在 ClearCorrect 的 ITC 裁決中,即使在上訴期間,如果他們仍在進行數位化治療規劃,可能會面臨相當高的按日罰款風險。所以第一,我這樣理解對嗎?第二,這是否與你剛才提到他們可能在為 SmileCareClub 的病例做治療規劃有任何關聯?我想知道從這個角度看,對他們是否有任何影響或潛在風險?
Roger George - VP Legal Affairs, General Counsel
Roger George - VP Legal Affairs, General Counsel
I don't remember specifically what the ruling is on damages in the interim, but it is continued infringement from our point of view. And it doesn't affect -- it is the same thing whether they are doing it for themselves or whether they are doing it for SmileCareClub.
我不太記得裁決對於過渡期間損害賠償的具體內容,但從我們的角度來看,那仍然是持續侵權。而且不會有差別——不論他們是為自己做,或是為 SmileCareClub 做,都是同一件事。
Jeff Johnson - Analyst
Jeff Johnson - Analyst
Okay, that's helpful. Maybe I will ask a couple more off-line on that later tonight. Thanks, guys.
好的,這很有幫助。也許我今晚稍晚會再私下追問幾個問題。謝謝各位。
Operator
Operator
Jon Block, Stifel.
Jon Block,Stifel。
Jon Block - Analyst
Jon Block - Analyst
I will focus on utilization. The year-over-year GP utilization was up for the second straight quarter, after being down every quarter in 2014. So, Joe, can you talk about the sustainability here with that increase with the greater sales rep count and maybe where you are with the sales initiative in that really long GP tail?
我會聚焦在使用率(utilization)。一般牙醫(GP)使用率的年增率已連續第二季上升,而 2014 年每一季都是下滑。所以,Joe,你能談談在銷售代表人數增加的情況下,這個提升的可持續性如何?以及你們在那條非常長的 GP 長尾市場上的銷售計畫目前進展到哪裡?
And then, part two to that would be in the ortho channel, the utilization increases have been huge and can that continue with the current, call it, G portfolio or should we expect or need another iteration on that front?
第二部分是在矯正(ortho)通路,使用率的提升幅度很大;在目前這個(姑且稱之為)G 產品組合下,這樣的提升能否延續?還是我們應該預期或需要在那方面再推出下一次迭代?
Joe Hogan - President, CEO
Joe Hogan - President, CEO
Hi, Jon. I think on the ortho channel side -- I will just start that question before I back up the GP -- is I think you will see -- I'm just getting used to the statistics in this business, but I think you'll see that it normally goes down from third quarter to fourth quarter on the penetration rate. It has to do with the teen cases that tend to come in in the third quarter versus the fourth quarter.
嗨,Jon。我先回答矯正通路那邊——我還在適應這個行業的統計口徑——但我認為你會看到,滲透率通常會從第三季到第四季下降。這與青少年病例通常在第三季多於第四季有關。
So I think what you might see is a little lower penetration rate on the ortho side for North America as we go into the fourth quarter, but that's just statistical and based on year to year. There is nothing in the sense of the demand pattern to think that we see any interest that we have in orthos on that.
所以我認為,當我們進入第四季時,你可能會看到北美矯正端的滲透率略低一些,但那只是統計上的現象、基於逐年比較。就需求型態而言,沒有任何跡象讓我們認為矯正醫師端的興趣會受到影響。
On the GP side, Jon, I am just -- again, my newness in this business makes me more cautious than I normally am. But what -- the correlation I see right now on the GP side is you have to make sure that you continue to approach this market in the GP side with salespeople because it is hard for us to have any really meaningful increase when you look at the amount of utilization that is going on in that channel.
在 GP 端,Jon,我只是——再說一次,我在這個業務上的資歷尚淺,讓我比平常更為謹慎。但我目前在 GP 端看到的關聯是:你必須確保持續以業務人員的方式來切入 GP 端市場,因為當你看這個通路的使用率(utilization)時,我們要取得任何真正有意義的提升都很困難。
And so we have proven so far, I think, in 2015 is you add salespeople to this, to the marketplace, we continue to get growth. There is some sales models that we are transferring in from -- in Europe from a penetration standpoint that we are going to employ in North America next year as a trial to see if we can help with some of that penetration. That will apply both to ortho and GP, too.
因此,到目前為止我們在 2015 年所證明的是:只要在這個市場上增加業務人員,我們就能持續成長。另外,我們會把一些在歐洲、從滲透率(penetration)角度所採用的銷售模式移轉過來,明年在北美先做試行,看看是否能協助提升部分滲透。這會同時適用於矯正(ortho)與 GP。
You know, secondly, is, and we talked to before about the sales associates that we have added recently, which are basically what I would say back-office support that actually make phone calls and all to customers and not direct. We have seen some success with that model, too, and I think that might help us on the GP sector also in the sense of how do we go about that, how do we really -- I have talked about this before, too, Jon. How do we really segment that marketplace to see where we think we can get further penetration with doctors that are truly interested in taking Invisalign to another level versus doctors that might just be curious on it and wanting to work with it, not necessarily in the in-depth way that we would want.
你知道,第二點是——我們之前也談過我們最近新增的銷售助理(sales associates),基本上我會把它們視為後勤支援(back-office support),實際上會打電話等方式聯繫客戶,但不是直接面對面的銷售。我們也看到這個模式有一些成效,我認為它也可能在 GP 領域幫到我們,因為這牽涉到我們要怎麼做、要怎麼真正——Jon,我以前也談過。我們要如何真正把市場做分眾(segment),找出我們認為能進一步提高滲透率的醫師——也就是那些確實有興趣把 Invisalign 提升到另一個層次的醫師——相對於那些可能只是好奇、想試著用用看,但不一定會以我們希望的那種深入方式來操作的醫師。
Jon Block - Analyst
Jon Block - Analyst
Okay, perfect. Very helpful. And then (multiple speakers)
好,完美。非常有幫助。然後(多位發言者)
Joe Hogan - President, CEO
Joe Hogan - President, CEO
(multiple speakers). I know that's a lot, Jon. That's a lot.
(多位發言者)。我知道這很多,Jon。真的很多。
Jon Block - Analyst
Jon Block - Analyst
No, that's a lot?
不,這很多?
Joe Hogan - President, CEO
Joe Hogan - President, CEO
Yes.
是的。
Jon Block - Analyst
Jon Block - Analyst
It's a lot, but it's all very helpful, so I appreciate that.
很多,但都非常有幫助,所以我很感謝。
And then, David, just to shift gears for a second, you got the question earlier on leverage and your commentary was, well, revenues are up and OpEx is down and there is not -- that doesn't happen too frequently.
然後,David,先換個話題,你先前被問到槓桿(leverage)時,你的評論是:營收上升、營運費用(OpEx)下降,而這種情況並不常見。
And I'm not asking for 2016 guidance, but I just want to make sure. We have had situations before where your 4Q to 1Q, your leverage is usually down pretty dramatically because you have got some one-time expenses that get re-upped. Can you give any color around leverage as we look out exiting 2015 into 2016, maybe near-term/long-term, because again the move from 3Q to 4Q is just tremendous. Is there anything that comes back into play on the OpEx front once we enter 2016? Thanks, guys.
我不是在問 2016 年的指引(guidance),但我只是想確認一下。我們以前遇過一些情況:從第 4 季到第 1 季,你們的槓桿通常會明顯下滑,因為有一些一次性費用會重新回來。你能否就槓桿提供一些說明,當我們從 2015 年結束走向 2016 年時,可能是短期/長期的觀點?因為第 3 季到第 4 季的變化真的非常大。一旦進入 2016 年,在 OpEx 端是否有任何項目會重新回到費用結構裡?謝謝各位。
David White - CFO
David White - CFO
So to the first part of that that you asked as it relates to some of the seasonality you might see in our performance, financially and so forth, you're right to call that Q1 typically is down for us, and largely for things that are external to the Company, like the fact that payroll taxes start over and we have a lot of employees here in the US whose payroll taxes start over and our portion of that that we have to pay.
就你問的第一部分、也就是你可能會在我們財務表現等方面看到的一些季節性而言,你指出得沒錯:第 1 季通常對我們來說會下滑,而主要原因多半是公司外部因素,例如薪資稅(payroll taxes)會重新起算;我們在美國有很多員工,他們的薪資稅會重新起算,而我們也必須支付其中公司應負擔的部分。
At the same time, we have internal items that influence that, such as we have focal salary reviews and increase -- performance reviews and increases at that point in time. So those all put pressure, you might say, on operating-expense uplift in Q1.
同時,我們也有一些內部因素會影響,例如我們會在那個時間點進行重點薪資檢視與調薪——績效考核與加薪。因此,這些都會對第 1 季的營運費用上升(operating-expense uplift)造成壓力。
And then when you add to that the fact that when we go through our annual operating plan cycle, we go through a process that looks at basically our baseline organic business in terms of what do we think our business can sustain without any additional resources, and then we look at that relative to where do we have investment opportunities and how would those investment opportunities drive both short-term, as well as long-term, growth of the topline and penetration into the business?
再加上,當我們進行年度營運計畫(annual operating plan)循環時,我們會走一個流程:先看我們的基礎有機業務(baseline organic business),也就是在不增加任何額外資源的情況下,我們認為業務能維持到什麼程度;接著再對照我們有哪些投資機會,以及這些投資機會將如何同時推動短期與長期的營收成長(topline growth)以及業務滲透(penetration)。
And a lot of times, those investments all get made early in the beginning of the year as well, and this last year -- this year we are currently in is a case in point. We made investments in all three of our regions at the beginning of the year to begin driving further penetration within the existing doctors and bringing new doctors into the family, so to speak.
而很多時候,這些投資也都會在年初較早的時點就做出來;去年——也就是我們目前這一年——就是一個例子。我們在年初對三個區域都做了投資,以進一步推動既有醫師的滲透,並把新醫師帶進來——可以說是加入我們這個大家庭。
So there is that piece of it, and I think you should anticipate that we will, as our historical pattern has shown, that we will be making large investments, incremental investments, as we move into 2016 and that will create some downward pressure on Q1, and hopefully by the time we get to the end of the year, we begin seeing a lot of uplift to our business as we are seeing this year.
所以有這一塊,我認為你應該預期:依照我們過去的歷史模式,當我們邁入 2016 年時,會進行較大、增量性的投資,而這會在第 1 季造成一些向下壓力;並希望到了年底時,我們能開始看到業務有很大的拉升(uplift),就像今年所看到的一樣。
Longer term than that, Joe mentioned the fact that we see a pretty good correlation between our investments that we make in the field and investments that we make in products, one driving adoption, the other driving doctor coverage and so forth. I think that will be our business for the while.
更長期來看,Joe 提到我們看到一個相當不錯的關聯:我們在前線(field)的投資與我們在產品上的投資,一個推動採用(adoption),另一個推動醫師覆蓋(doctor coverage)等等。我認為這將會是我們一段時間內的經營方式。
I think our challenge long term is finding the right balance between the investments that we believe we can execute on and, at the same time, be good caretakers, being financially responsible for finding that right balance between our short-term performance and our long-term performance. So our long-term model that we've talked about historically, we still believe that's the right model for us and that's where we will continue to strive the business.
我認為我們長期的挑戰,是在我們相信能夠落地執行的投資與同時做好管理者、在財務上負責任之間,找到正確的平衡點,也就是在短期表現與長期表現之間找到適當的平衡。因此,我們過去一直談到的長期模型(long-term model),我們仍然相信那對我們是正確的模型,而我們也會持續朝那個方向努力推動業務。
Jon Block - Analyst
Jon Block - Analyst
Perfect. All right, thanks, guys.
完美。好,謝謝各位。
Operator
Operator
Chris Lewis, ROTH Capital Partners.
Chris Lewis,ROTH Capital Partners。
Chris Lewis - Analyst
Chris Lewis - Analyst
Thanks for taking the questions. Wanted to start on the fourth-quarter gross margin guidance. When I think about ASPs ticking up sequentially, along with the strongly implied sequential case volume growth, midpoint of the fourth-quarter gross margin guidance implies a flattish level from the third quarter. So can you just walk us through the factors that are layering into that outlook, despite the sequential ASP and volume pickup?
謝謝讓我提問。我想先從第四季毛利率指引(gross margin guidance)開始。當我想到 ASP 逐季上升,再加上強烈暗示的逐季病例量(case volume)成長,第四季毛利率指引的中位數意味著與第三季大致持平。所以你能否帶我們走一遍:儘管 ASP 與量都有逐季回升,這個展望背後有哪些因素疊加在一起?
David White - CFO
David White - CFO
Well, we do have some ASP uplift, but we also have a higher training volume during this quarter, which typically is with lower gross margin. So that tends to hold some of that uplift back as a result.
嗯,我們確實有一些 ASP 的提升,但本季的培訓量(training volume)也較高,而培訓通常伴隨較低的毛利率。因此,這會使得部分提升被抵銷。
The other piece of it is that we are shipping our Element product this quarter, and Element, although it is a much better business model, you might say, for our Company in many respects and I think also for the doctor, and it does have a higher gross margin than the older version, it is still below our Clear Aligner overall gross margin.
另一個因素是:我們本季在出貨 Element 產品;Element 雖然在很多面向上可以說對公司是更好的商業模式,我想對醫師也是,而且它的毛利率也高於舊版本,但它仍低於我們透明牙套(Clear Aligner)整體的毛利率水準。
And so as that Element business picks up, that also puts some downward pressure, you might say, on the gross margin, just from a mix standpoint.
因此,隨著 Element 業務成長,從產品組合(mix)的角度來看,也會對毛利率造成一些向下壓力。
Chris Lewis - Analyst
Chris Lewis - Analyst
And on the OSA market opportunity, can you talk about that decision and potentially quantify the impact that will have on R&D spend going forward? Thanks.
關於 OSA 市場機會,您能談談做出該決定的考量,並且可能量化一下這將對未來研發支出造成的影響嗎?謝謝。
Joe Hogan - President, CEO
Joe Hogan - President, CEO
I will let David do the quantification, Chris. I would just say that we -- when you look at that, it is not that we didn't think that OSA was a good market. In fact, it might be a good market for some company at some point in time in a sense of how that can compete against other kinds of opportunities out there.
Chris,我讓 David 來做量化說明。我只想說,當你看這件事時,並不是我們認為 OSA 不是個好市場。事實上,從某種意義上說,對某家公司在某個時間點而言,這可能會是一個好市場,取決於它如何與其他各種機會競爭。
But from us, we have, I feel, much better places in our core market to invest that money right now and that's what we're going to do in the future is just stay focused.
但就我們而言,我覺得在我們的核心市場裡,現在有更好的地方可以投資這筆錢,而這也是我們未來要做的——就是保持專注。
David White - CFO
David White - CFO
And back to your question about impact, we gave some guidance at the beginning of year that we thought OSA would be somewhere around a 1-point cost on revenue, and you'll see in the slides that we provided on the webcast, in the quarter the wind-down cost on that was about $0.02 a share.
回到你關於影響的問題,我們在年初曾給過一些指引,當時我們認為 OSA 大約會對營收造成 1 個百分點的成本影響;你也會在我們於網路直播提供的投影片中看到,本季該項目收尾(wind-down)成本約為每股 0.02 美元。
Chris Lewis - Analyst
Chris Lewis - Analyst
Okay, thanks for the time.
好的,謝謝撥冗。
Operator
Operator
Richard Newitter, Leerink Partners.
Leerink Partners 的 Richard Newitter。
Ravi Misra - Analyst
Ravi Misra - Analyst
Hi, thanks. It is actually Ravi. Thanks for taking the follow-up again. I have a question maybe on ASPs by product segment of the Express and the Lite segment. It looks like it stepped down a little bit again sequentially. How should we think about that going forward, in terms of is this the new normal or should we continue to expect price declines from this area?
嗨,謝謝。其實我是 Ravi。謝謝再次接受追問。我想問一下 Express 與 Lite 這兩個產品區隔的 ASP(平均銷售價格)。看起來它又較前一季小幅下滑。我們該如何看待未來走勢?這是新的常態,還是我們應該預期從這個水準繼續降價?
David White - CFO
David White - CFO
As we have talked about in the past, there is a lot of variables that make up our ASP and they come down -- if I summarize them at the highest level, they come down to product mix, doctor mix, and -- let me focus on those two for a second.
如同我們過去談過的,影響我們 ASP 的變數很多;如果我用最高層次來總結,主要是產品組合、醫師組合——我先聚焦這兩點說明。
So when you think -- when you look at product mix, certainly lower-stage products and so forth are going to drive down -- all other things being equal, a richer mix of lower-stage products will obviously bring ASPs down. And you will see -- and from time to time, you're going to see us running promotions and so forth to incent doctors to give those low-stage cases tries and so forth.
當你思考——當你看產品組合時,較低階段的產品等,當其他條件相同時,會拉低 ASP;更高比例的低階段產品組合,顯然會讓 ASP 下降。而你也會看到——我們不時會推出促銷等措施,來激勵醫師嘗試那些低階段的病例等。
But, ultimately, our objective for many doctors is to treat those and to get them to not only treat the simple cases, but get them to build their clinical competence on those simple cases and begin adopting full cases where they feel they are capable and confident that they can do so.
但最終,我們對許多醫師的目標,是讓他們治療這些病例,不僅處理簡單病例,也在簡單病例上建立臨床能力,並在他們覺得有能力且有信心時,開始採用完整病例(full cases)。
So you're going to see some ups and downs on product mix, and as we introduce new products in the future and so forth, I think you can anticipate that when most of our R&D effort is focused on improving the clinical efficacy in those more complex cases, I think you'll see pressure from a product-mix standpoint going in the other direction.
因此你會看到產品組合有一些起伏;而且隨著我們未來推出新產品等,我認為你可以預期,當我們大部分研發投入都聚焦在提升較複雜病例的臨床療效時,從產品組合的角度,壓力可能會往相反方向移動。
So I wouldn't be too fixated, I think, on the last quarter or so as we have ran some promotions on that case. We have said over time that -- over the long period, we think ASPs can be relatively stable, plus or minus, and the other piece that enters into it, the second piece, is -- I forgot to mention -- is when you look at the types of doctors we are bringing in.
所以我不會太執著於上一季左右的情況,因為我們針對那類病例做了一些促銷。我們長期以來一直說——從長期來看,我們認為 ASP 大致可以相對穩定、上下小幅波動;而另一個會影響的部分、第二個部分是——我剛剛忘了提——也就是我們引進的醫師類型。
So as we dabble and penetrate and so forth the GP market, those doctors that are submitting lower cases are typically paying higher prices for those cases. As those doctors get engaged, whether GPs or orthos, they have an opportunity to participate in volume discounts.
因此,當我們在 GP(一般牙醫)市場試水溫並逐步滲透時,那些提交較低階病例的醫師,通常會為那些病例支付較高的價格。當這些醫師開始投入,不論是 GP 或矯正科(orthos),他們都有機會參與量販折扣(volume discounts)。
And so as we improve utilization in either the GP channel or in the ortho channel, we basically share, you might say, with those doctors some of the economic benefits of that adoption, from the standpoint they get the higher discounts and, of course, we are getting more volume as a result.
因此,當我們提升 GP 通路或矯正通路的使用率時,基本上我們會把採用所帶來的一些經濟效益「分享」給這些醫師——從他們的角度來看,他們能拿到更高的折扣;當然,我們也因此獲得更大的出貨量。
And depending upon how that mix is from one quarter to the next, you are going to see some volatility, you might say, in ASPs. So for example in Q3, we know it is a heavy quarter for teens, particularly here in North America, and that typically goes to orthos. And when you look at ortho adoption, our ortho doctors are typically the ones that participate more regularly in those advantaged-pricing tiers and so forth.
而且視每一季之間的組合變化而定,你會看到 ASP 出現一些波動。例如在第三季,我們知道青少年(teens)占比很高,特別是在北美,而這通常會流向矯正科。當你看矯正科的採用情況時,我們的矯正科醫師通常是更常參與那些優惠定價級距(advantaged-pricing tiers)等的族群。
So, I wouldn't get too fixated with some ups and downs you're going to see quarter to quarter, and as I said a minute ago, over the long term we think ASPs will be stable, plus or minus.
所以,我不會太執著於你會看到的季度間起伏;如同我剛才說的,長期來看我們認為 ASP 會大致穩定、上下小幅波動。
Ravi Misra - Analyst
Ravi Misra - Analyst
Great, thank you for the very detailed response. Appreciate it.
很好,謝謝你非常詳細的回覆。感謝。
Shirley Stacy - VP Corporate Communications & IR
Shirley Stacy - VP Corporate Communications & IR
Well, everyone, I think this concludes our call today. We appreciate your time and look forward to seeing you at upcoming conferences and industry meetings. If you have any follow-up questions, please contact investor relations. Have a great day.
各位,我想今天的電話會議就到這裡結束。感謝各位撥冗,也期待在接下來的各項會議與產業活動中與各位見面。若有任何後續問題,請聯絡投資人關係部門。祝各位有美好的一天。
Operator
Operator
Thank you. This does conclude today's teleconference. You may disconnect your lines at this time. Thank you for your participation.
謝謝。今天的電話會議到此結束。您現在可以掛斷電話線。感謝您的參與。